Earnings Labs

BIO-key International, Inc. (BKYI)

Q3 2014 Earnings Call· Thu, Nov 13, 2014

$0.51

-15.22%

Key Takeaways · AI generated
AI summary not yet generated for this transcript. Generation in progress for older transcripts; check back soon, or browse the full transcript below.

Same-Day

+7.69%

1 Week

-23.08%

1 Month

-15.38%

vs S&P

-12.31%

Transcript

Operator

Operator

Good morning, ladies and gentlemen. Thank you for standing by. Welcome to the BIO-key International, Incorporated fiscal 2014 third quarter conference call. (Operator Instructions). As a reminder ladies and gentlemen, this conference is being recorded today November 13, 2014. I would now like to turn the call over to your today's host, Jay Meier, BIO-key's VP of Corporate Development. Sir, you may begin.

Jay Meier

Operator

Thank you. Good morning, everyone, and thank you for joining us today for our fiscal 2014 third quarter financial report conference call and webcast. With me this morning are Mike DePasquale, BIO-key's Chairman and Chief Executive Officer; and Ceci Welch, BIO-key's Chief Financial Officer. I'll begin the call by reading our customary Safe Harbor statement, after which Mike and Ceci will review our results and milestones, before opening up the call for Q&A. This morning BIO-key issued its fiscal 2014 third quarter financial results. The press release is available in the Press Release section of our website at www.bio-key.com. Additionally, the call is being webcast live on our website and the replay will be available for 30 days beginning one hour after the completion of this call. The replay may be accessed by calling 877-344-7529 in the U.S. or 412-317-0088 internationally. And the access code for the replay is 10055289 followed by the pound key. I'd like to remind everyone that today's conference call and webcast may contain forward-looking statements that are subject to certain risks and uncertainties that may cause actual results to differ materially from those projected on the basis of these statements. The words, estimate, project, intends, expects, believes, and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs as well as assumptions made by and information currently available to management pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. For a more complete description of these and other risk factors that may affect the future performance of BIO-key International, see Risk Factors in the company's Annual Report on Form 10-K and its other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. The company also undertakes no obligations to disclose any revision to these forward-looking statements to reflect events or circumstances after the date made. At this time, I'd like to turn the call over to Mike.

Michael DePasquale

Analyst

Thank you, Jay, and welcome, everyone. And thank you for joining us for the BIO-key fiscal 2014 third quarter report conference call. We're glad to be here today to discuss our most recent results. Q3 was a good quarter and very much improved from the previous one. The industry continues to emerge and we are emerging with it. Our sales have been a bit volatile this year and in Q3 we benefited from the volatility with record Q3 revenue that exceeded our expectations. Further while our pipeline remains robust and we forecast a respectable Q4 and fiscal year, we remain emergent and potentially volatile. And so we are applying disciplines to manage our fresh working capital and operations as efficiently as possible in preparation to the day when market demand requires all available resource and bandwidth. We think that 2104 could be the best year in BIO-key's history as a standalone biometric vendor. But as the industry emerges and our channels develop, we continue to see our opportunity horizon improve and so we have several tings to discuss. As always I'll start by framing our presentation of envision for the industry, its emergence and in particular how it's changing. Now I'll put some color on our Q3 results followed by CC summary of the financial details. Then I'll provide a little more context for our Q4 guidance and finally will open the call for Q&A. It's no secret that biometrics and more specifically finger biometrics are beginning to go mainstream with consumers. With Apple first introducing Touch ID and more recently Apply Pay, one of the first payment offerings in the market to include finger biometrics, consumers are clearly accepting the ease-of-use and convenience that finger scanning provides. Also, the deployment of finger scanners on Samsung devices, as well as…

Ceci Welch

Analyst

Thank you Mike. Total revenue for the three months ended September 30, 2014 was $1,283,847 compared to Q3 2013 revenue of $431,576, an increase of $197%. Sales grew largely as a result of higher license sales in addition to higher service revenue. Q3's 2014 growth increased to 81% from 76 in Q3 2013. Operating expenses grew third quarter in 2014 increased 20% to $1,315,000 from approximately $1,094,000 in Q3 2013 and were sequentially flat. Net loss for Q3 2014 were $51,526 which decreased from Q3 2013 net loss of $782,544. Q3 2014 earnings per share were less than $0.01, a loss of a $0.01 versus Q3 2013 earnings per share of a loss of $0.01. Total revenue for the nine months ended September 30, 2014 was $3,054,158, compared to $1,658,476 for the same period ending September 30, 2013, an increase of 84%. For the nine-months period ended September 30, 2014, gross margin increased to 83% from 81% the same period in 2013. Operating expenses for the period increased 36%, year over year, to approximately $4,024,000, from approximately $2,957,000 in 2013. Net loss for the nine months September 30, 2014 was $1,377,026, or $0.01 per share, which decreased from a net loss of $1,652,963, or a loss of $0.02 per share, for the period ended September 30, 2013. The Company reported cash, cash equivalents, and accounts receivables of $798,753 as of September 30, 2014, as compared to $902,578 at June 30, 2014. And now back to you Mike.

Michael DePasquale

Analyst

Thank you Ceci. Now we should discuss our future including Q4 2014 guidance. Last quarter we reiterated our view that our pipeline opportunities are often large and hard to predict. Given our Q3 results, I think we should reiterate this once again. The opportunities typically pursue can often exceed several $100,000 in value. The timing of the recognition of such orders can materially impact quarterly results, both negatively as well as positively. Therefore we continue to recommend evaluating our progress over a longer period of time. This trend will continue for some time but we'll smooth this out over time. It will smooth primarily as we increase the number of sales channels, penetrate them more deeply and grow such that individual orders become relatively small compared to our overall size. As noted, we started the quarter with a total sales pipeline of roughly $30 million and our pipeline currently stands at just under $30 million. For clarity, the opportunity pipeline as the total value of deals that we could win within the next 12 months. Opportunity pipeline is not backlog or bookings. We expect third quarter revenue to be between $1 million and $1.7 million. This range reflects the more conservative approach to guidance and budgeting that does include any one single potential large order or contract that may be awarded prior to the end of the year. We ended Q4 with solid bookings expected to ship during Q4; therefore we have high confidence in the low end of that guidance range. We expect gross margin to remain at around 85%. We further expect to generate operating profit with incremental revenue about $1.5 million. Our headcount remains at about 20 employees plus a number of contract developers. We anticipate adding more resources incrementally in both sales and R&D through the course of next year as our business grows. As you can see at this point, despite some volatility, our business appears to be ramping. Year-to-date our sales have grown 84% over 2013 and we are tracking towards a record 2014. We're very encouraged and expect this trend to continue. We believe we are prepared for substantial growth that we hope may have begun in 2014 and will continue well into the future. I'd like to personally thank our very patient shareholders and friends. And now I expect you all have questions for us. So operator let`s start the Q&A.

Orin Hirschman - AIGH Investment Partners

Analyst

Michael DePasquale

Analyst

Clearly there are a number of components. Most importantly, it’s the regulatory drivers. It’s the fact that electronic prescribing now is beginning to be mandated across the States. We saw it mandated in New York. This year by March of 2015 all prescriptions that are written must be electronic and given that they have to be electronic, they need to be authenticated to doctor, the physician, the physician's assistant needs to authenticate with multifactor authentication and biometrics is one of those factors. So it's clearly the regulatory drivers that are really accelerating the business. The second is that our partnerships are maturing. We have some very, very good marquee customers like the Cleveland Clinic and Nationwide Children's Hospital and Xoma [ph] Health and Genesis Health, Rady's Children's Hospital in California. So that's Epic and Allscripts, the big EMR providers are starting to really get on board. Their sales reps are recognizing that we have been successful, BIO-Key biometrics have been successfully deployed and given that they can generate incremental sales revenue on their paper, we're starting to see that kind of have an effect. So it's coming together nicely for us.

Orin Hirschman - AIGH Investment Partners

Analyst

The new mandates have been out there for a while. Is it just a matter at the time now that rush is finally on because they waited and they waited and they waited?

Michael DePasquale

Analyst

Yes for example in New York, there were hospitals under tremendous pressure to get this deployed by the end of March. The state is not going to wave the deadline this go around. But what I think is driving it more than anything else is, there's always been a need to access a patient record securely and multifactor authentication has been required that in some instances, where it's absolutely mandated is e-prescribing and that is kind of a new wave that the DEA and each of the states and the Federal DEA are really driving. So I think that's what's changing things right now, it's really more along e-prescribing that's driving biometrics.

Operator

Operator

And our next question will come from Dan Cammis. Go ahead please.

Dan Cammis

Analyst

I couldn't quite tell, are the warrants adjusted on their reverse split or will they be sold at $0.15, can you give that split?

Michael DePasquale

Analyst

No, everything will be adjusted (indiscernible) after the split. So, everything gets equally adjusted, warrants, primary shares, everything is adjusted after the split, the reverse.

Dan Cammis

Analyst

And is it going to be one for two or is it just the minimum?

Michael DePasquale

Analyst

No, it looks like it's going to be one for two and the simple facts around that are really to maintain liquidity in the stock. What investors want and what we believe is critically important is they are focused on two things, right. The share price and also the liquidity. Even if we were able to affect a more significant reverse ratio, it still wouldn’t get us other than doing something astronomical; it wouldn’t get us to another exchange or another level without drying up liquidity. So for example, if we only had 10 or 15 million shares outstanding, there is a good chance that we have tremendous volatility in the share price and again liquidity would dry up. So we don't want to do that. We think our business will grow. We think that we have opportunity to create, increase and enhance valuation and I think we can do it at this level. The two for one gives us clearly the potential to not only facilitate this transaction, but also to ensure that we can fund the company going forward, should we require and it be necessary for us to do that. So reducing the -- or I should say reducing the number of shares outstanding that fit with under the authorized share account is very important for us in the near term.

Dan Cammis

Analyst

Do you have any kind of timing on it now?

Michael DePasquale

Analyst

Yes, we are going to move forward with the reverse immediately. So stay tuned if you're a shareholder you'll be receiving a package I would think in the next 30 to 60 days.

Dan Cammis

Analyst

Okay. Find Biometrics reported that you guys purchased 75,000 NEXT readers. Are you selling those currently? Have they been delivered and can you tell us how your -- how the sales of readers you’ve got a few readers now you're selling, is that actually a growing business or is that to be the?

Michael DePasquale

Analyst

Actually that's a business that we see growing but more importantly we see providing a full and complete solution including these readers as a way to catalyze our software business. So, what customers are looking for is one throat to choke, they are looking for a supplier than can provide them the sensor, the software and the services integration to their applications. Developers are looking for that as well. We have purchased sensors from NEXT Biometrics. They have a very large placement sensor which is very inexpensive. We purchased the sensor modules and we will be putting them in a package and making them available in the market likely towards the end of this year. So that's underway right now. This is going to be a revolutionary device with revolutionary pricing. And that will be again available as we get to the end of the year beginning of next.

Operator

Operator

And our next question will come from Ed Schwartz of Schwartz Investments.

Ed Schwartz - Schwartz Investments

Analyst

You talked both last quarter and this quarter about sales opportunities. I think the last quarter you said you had a backlog of like 10 million in sales, opportunities. If my memory is correct, how much of that backlog in the Q3 did you convert into actual sales?

Michael DePasquale

Analyst

Ed, let me just clarify. We talked about pipeline, not backlog.

Ed Schwartz - Schwartz Investments

Analyst

Yes sales pipeline backlog. Okay, we're on the same page.

Michael DePasquale

Analyst

Okay, so pipeline I think we said that our pipeline was about $30 million when we held our last call and our pipeline is approximately the same. It's about 29m. We converted over a $1 million in our pipeline in the previous quarter and that's reflected in our financial results. So it's very consistent.

Ed Schwartz - Schwartz Investments

Analyst

Okay and what do you expect to convert this quarter?

Michael DePasquale

Analyst

Well our guidance which I just described and what's described in our press release were for us to generate between $1 million and $1.7 million in revenue and that's exclusive of any one single large opportunity that may or may not close the fourth quarter. So you can look for us to convert somewhere between $1 million and $2 million of that pipeline in the fourth quarter.

Ed Schwartz - Schwartz Investments

Analyst

Okay. And just from a consumer point of view and a personal point of view, I just came from a trip to Europe, only to find out that someone had gotten my credit card and had wiped out my bank account. How can I -- and most of this was on online purchases, how can I force my bank to have a biometric on my computer whenever there is an online purchase to -- so that there is no credit card fraud.

Michael DePasquale

Analyst

Yes, that's a very, very good question and something that we obviously have a very strong interest in. We've mentioned not only in our last call but I mentioned again that t we're involved in a number of banking opportunities which will include finger capability at the ATM so there would be ATMs that actually have finger scanners in them. There will be finger scanners in the branches at these banks and they will ultimately allow and include finger capability for online banking. So it is something that's evolving. I hate to say it, but its evolving internationally faster than its evolving here in the US. But I have a feeling that you're going to start to see that turnaround. In fact Jay Meier, who's our VP of Corporate Development had a lot to say quite frankly especially as it relates to payments and banking and maybe I'll just let him make a comment here as well. But it will happen in the US, just a little more slowly than international.

Ed Schwartz - Schwartz Investments

Analyst

All right and do you have an international presence to take advantage of that market?

Michael DePasquale

Analyst

Clearly we do. We don't directly -- as you know we've done a lot of international business through the years. We do it through credible partners and the integration partners that or technology partners that we're working with in these countries generally are very large players have significant presence, significant resources and capability to deliver projects to again (indiscernible). So that's the way we do business on the international front.

Operator

Operator

(Operator Instructions). Our next question will come from Matt Chambers. Please go ahead, sir.

Matt Chambers

Analyst

Quick question about IDEX, as far as I remember, they were on -- they were set to release their new technology first quarter of next year. Is that still planned? Can you comment at all on that?

Michael DePasquale

Analyst

Yes I can. Actually I commented on it also point you to their website. They did their earnings call quarterly report yesterday and (indiscernible) who was their CEO did a very eloquent presentation on their -- on the status of their products and so far, so good. They are tracking to first quarter 2015 to be sampling their first placement sensor and also their swipe which will include our software. So it appears that they are tracking right now and helping to those commitments.

Matt Chambers

Analyst

And InterDigital and AMD, we haven't heard anything about them lately specifically. Do you have an idea of approximately when you expect revenues from these two?

Michael DePasquale

Analyst

Yes, let`s take them separately. InterDigital, we continue to work with InterDigital. We have as you know develop, call it a high level solution, multi-factor authentication platform, single sign-on platform for the mobile market with them and we continue to evolve that. So our engineering teams are continuing to work together and we are in process of figuring out our go to market strategy and exactly what and how we're going to take that product to market. So that's in place and in motion and we still have a very, very tight closely coupled relationship. AMD, we are in the process of affording and you're going to hear more on this from us and maybe in a formal press release. We are in the process of porting our software to the TrustZone or Trustonic secured elements platform which will be part and parcel of the AMD deployment. So all of that is evolving as well and our technology folks are engaged in that right now.

Matt Chambers

Analyst

So InterDigital, they have their product as finished, you're in it, you're just about ready to launch, is that right or?

Michael DePasquale

Analyst

I can't say that it's finished but its evolving. And it's really evolving because some of the standards are changing, we want to make sure that when we do go to market that we meet all the market requirements. So we're still evolving again with our engineering groups. But again we'll be at the -- we'll be at all the big events next year discussing that product and we have already discussed that particular product with some very, very large players. So it's not as if we're not selling it today, but I think we'll be much more aggressively pursuing the market in 2015 with that product.

Operator

Operator

And we do have a question from Irene McGrath.

Irene McGrath

Analyst

Mike this question is for Jay, just off of Mr. Schwartz's segment with regards to how the international markets are developing faster than ours in that certain vein. Could you elaborate on that Jay as Mike you said, Jay might be able to?

Jay Meier

Operator

Sure, there is a couple of things going on internationally. First of all, some of the infrastructure that exists internationally is not quite as sunk as the infrastructure in the United States so that you don't have to accommodate a huge fixed investment necessarily in something and navigate around that. In other words, you don't have to -- you may not have to rip out a high valued network in order to or other technology to accommodate a new infrastructure. Secondly and maybe even more importantly, culturally the United States values individual privacies and things like that, other countries don't have that same cultural stand on that and so biometrics tends to emerge a little bit more quickly there. And thirdly it is starting to happen in the United States, but as Gartner pointed out in their Digital Banking Services Hype Cycle, it's just entering the marketplace, but we're definitely seeing activity in the United States and interest. The sales cycle on these things can be a bit long. There is a lot of engineering; there is a lot of questioning because the risks are very high in banking unlike payments. But it's definitely happening.

Operator

Operator

Dan Cammis

Analyst

Are you seeing or who are you seeing showing up as competitors in healthcare market now that's reaching critical mass?

Michael DePasquale

Analyst

The competitors in this space are some of the single sign-on vendors where to some regard they are competitors but they are partners. So for example Imprivata is a company that most recently went public. They IPOed recently. They have a single sign-on platform and they have a biometric solution that goes along with it. Unfortunately its inferior, it doesn’t meet the minimum standards and so it gives us an opportunity in these hospitals to compete for the biometric component of their overall deployment. We don't really see anybody else in any significant way especially with our key partners, with Epic and Allscripts who are really two really big players. We're not seeing anyone else that fundamentally could mean as a competitor to us. Generally speaking, when biometrics are requested or required, we're getting the call and we're engaged in the deal which is why as I described before, we've got over 100 pipeline opportunities in healthcare right now in our portfolio this quarter. So it's significant.

Dan Cammis

Analyst

Okay. What about competitors in the ATM market if that truly heats up?

Michael DePasquale

Analyst

Well keep in mind that the ATM like for example NCR ATMs will include finger scanners in them. But that's part of an ecosystem. It's not software are matching fingerprints on the ATM. It's matching the fingerprints back at the enterprise back on the server, whether it comes from the ATM or the branch or at home, it doesn’t make any difference. So the competitive nature of that -- the banking industry itself won't come from matching on the ATM. That is a pure enterprise solution and we have a very, very strong position when it comes to enterprise finger technology and you and patents to move the biometrics from device to the cloud. So that's an area where we are very, very strong.

Dan Cammis

Analyst

One last question, the pipeline growth, did it stall or do you think 29 million is where it will stay or it grew pretty fast there for a couple of quarters. This is the first ever it's stalling here in the quarter. So is there a reason for that or do you expect to continue to grow?

Michael DePasquale

Analyst

No I think we continue to expect to grow. I think it grew very quickly because of those banking opportunities that we discussed. So they were significant and they are bigger deals, so the pipeline grew more significantly. As you know things come in and things come out and that's going to happen virtually every quarter. But I would expect that our pipeline is going to grow -- continue to grow in a significant way over the next year for sure.

Operator

Operator

Michael DePasquale

Analyst

Thank you for participating in today's call. We hope that you will join us again for our next conference call to discuss our fourth quarter and full fiscal year 2014 results.

Jay Meier

Operator

Thank you for joining our conference call. As a reminder, this call will be available for replay one hour after the end of the call and it will be available for 30 days. The replay may be accessed by calling 877-344-7529 in the United States or 412-317-0088 internationally. The access code for the replay is 10055289 followed by the pound key. Thank you.

Operator

Operator

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.